Skip to main content

Sonic Genetics to Implement Translational Software PGx Platform in Australia

NEW YORK (GenomeWeb) – Sonic Genetics, a division of Sonic Healthcare, will implement pharmacogenetics decision support software from Translational Software (TSI) for its lab testing services in Australia.

The TSI knowledge platform provides flexible reporting, genomic decision support, and critical alerts regarding drug efficacy, toxicity, and known interactions, to guide clinical decision-making and enable physicians to prescribe the most effective medications. The software helps clinicians more closely tailor personalized treatments, according to TSI.

TSI's PGx platform includes clinical reporting for 65 genes and can be tailored to a variety of clinical specialties including cardiovascular, psychiatric, pain, internal medicine, and geriatrics. The platform is continually updated to prevent alert fatigue by only surfacing information that has the highest levels of evidence.

The platform also offers an API to enable software providers to expand their applications with the platform's PGx-based knowledge.

"We are pleased to extend our genetic testing services with Translational Software's PGx platform to help clinicians ensure more precise patient treatment," Colin Goldschmidt, CEO and managing director at Sonic Healthcare Limited, said in a statement.

Sonic Healthcare, based in Sydney, Australia, has 33,000 employees across Australia, New Zealand, the United Kingdom, Germany, Switzerland, Belgium, Ireland, and the US. Sonic Genetics has more than 1,850 accredited collection centers in Australia, according to the company website.